ESTA vs. AVNS, ZJYL, INGN, ENOV, DAWN, XNCR, MORF, PTGX, OMI, and NHC
Should you be buying Establishment Labs stock or one of its competitors? The main competitors of Establishment Labs include Avanos Medical (AVNS), Jin Medical International (ZJYL), Inogen (INGN), Enovis (ENOV), Day One Biopharmaceuticals (DAWN), Xencor (XNCR), Morphic (MORF), Protagonist Therapeutics (PTGX), Owens & Minor (OMI), and National HealthCare (NHC). These companies are all part of the "medical" sector.
Avanos Medical (NYSE:AVNS) and Establishment Labs (NASDAQ:ESTA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, community ranking, earnings and risk.
Establishment Labs received 29 more outperform votes than Avanos Medical when rated by MarketBeat users. Likewise, 62.22% of users gave Establishment Labs an outperform vote while only 54.97% of users gave Avanos Medical an outperform vote.
In the previous week, Establishment Labs had 2 more articles in the media than Avanos Medical. MarketBeat recorded 5 mentions for Establishment Labs and 3 mentions for Avanos Medical. Establishment Labs' average media sentiment score of 0.53 beat Avanos Medical's score of 0.50 indicating that Avanos Medical is being referred to more favorably in the media.
Avanos Medical presently has a consensus price target of $31.00, indicating a potential upside of 54.46%. Establishment Labs has a consensus price target of $55.00, indicating a potential downside of 7.28%. Given Establishment Labs' higher possible upside, equities analysts clearly believe Avanos Medical is more favorable than Establishment Labs.
Avanos Medical has a net margin of -9.15% compared to Avanos Medical's net margin of -53.12%. Establishment Labs' return on equity of 4.10% beat Avanos Medical's return on equity.
Avanos Medical has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Avanos Medical, indicating that it is currently the more affordable of the two stocks.
95.2% of Avanos Medical shares are held by institutional investors. Comparatively, 72.9% of Establishment Labs shares are held by institutional investors. 3.9% of Avanos Medical shares are held by company insiders. Comparatively, 11.4% of Establishment Labs shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Avanos Medical has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Establishment Labs has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500.
Summary
Avanos Medical beats Establishment Labs on 10 of the 18 factors compared between the two stocks.
Get Establishment Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for ESTA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ESTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Establishment Labs Competitors List
Related Companies and Tools
